Novel Biomarkers in Cardiac Surgery to Detect Acute Kidney Injury

$748,050R01FY2018HLNIH

Johns Hopkins University, Baltimore MD

Investigators

Linked publications & trials

Paper 38728094 Paper 38106577 Paper 37861689 Paper 37726051 Paper 37690632 Paper 37652206 Paper 37650762 Paper 37303083 Paper 37273234 Paper 37178093 Paper 37068906 Paper 36951957 Paper 36790467 Paper 36378029 Paper 36108888 Paper 35924345 Paper 35812275 Paper 35523653 Paper 35385337 Paper 35362481 Paper 35286453 Paper 35022767 Paper 35017169 Paper 34897925 Paper 34876454 Paper 34865148 Paper 34742616 Paper 34737201 Paper 34605718 Paper 34544821 Paper 34515046 Paper 34475336 Paper 34465605 Paper 34448642 Paper 34435718 Paper 34415356 Paper 34414423 Paper 34368666 Paper 34343625 Paper 33974569 Paper 33871887 Paper 33830227 Paper 33797560 Paper 33556265 Paper 33461986 Paper 33411068 Paper 33290282 Paper 33163720 Paper 33122288 Paper 33080002 Paper 33075389 Paper 33070369 Paper 33067383 Paper 33037129 Paper 32946505 Paper 32912935 Paper 32883700 Paper 32809268 Paper 32721447 Paper 32707221 Paper 32540406 Paper 32283087 Paper 32282046 Paper 32234829 Paper 31940606 Paper 31911262 Paper 31883805 Paper 31871123 Paper 31659071 Paper 31553978 Paper 31547939 Paper 31445275 Paper 31313951 Paper 31221679 Paper 31203275 Paper 31104561 Paper 30955944 Paper 30880140 Paper 30858225 Paper 30742783 Paper 30649998 Paper 30591223 Paper 30539650 Paper 30470437 Paper 30279274 Paper 30197965 Paper 29773711 Paper 29511889 Paper 29472416 Paper 29344362 Paper 29291759 Paper 29212948 Paper 29172665 Paper 29157119 Paper 29156498 Paper 28882126 Paper 28844586 Paper 28821332 Paper 28819997 Paper 28795578

Abstract

? DESCRIPTION (provided by applicant): The Translational Research Investigating Biomarker Endpoints (TRIBE) consortium is dedicated to enhancing the safety and outcomes in patients undergoing cardiac surgery by reducing the incidence and complications of acute kidney injury (AKI). In the prior two grant cycles, we enrolled 2200 adults and children undergoing cardiac surgery, collected peri- operative blood and urine samples, and measured novel biomarkers representing kidney injury, cardiac injury and inflammatory pathways in order to determine their association with AKI and three year mortality. In this competitive renewal, we will assess the utility of additional peri-operative biomarkers in blood and urine that represent repair, fibrosis and inflammation. With the existing and new biomarkers available in this cohort, we will create multi-marker panels to detect and quantify the spectrum of kidney injury. These will be included in the prediction models for long term events that will be built using validated, emerging and innovative statistical methods. The availability of reliable peri-operative clinical models for shot and long-term outcomes will assist in clinical decision-making and inform future biomarker-guided clinical trials. In adults, the risk prediction models will focus on recurrent cardiovasculr events and longer term mortality. In children, this project will serve as a foundational epidemiological study to be conducted as the first cohort to potentially link clinical AKI and kidney injury biomarkers with the future development of hypertension and CKD. We will also collaborate with other independent NIH sponsored AKI cohorts to validate the biomarker panels derived in the adult and pediatric cohorts. Our primary research aims are: Aim 1: To develop a peri-operative biomarker panel to optimally categorize and quantify the impact of cardiac surgery on the kidney and long-term health outcomes in adults. Aim 2: To determine whether clinical AKI and kidney injury defined by peri-operative biomarkers have long-term adverse effects among children after cardiac surgery. Aim 3: To validate multiplex biomarker panels of kidney injury markers in independent cohorts of adults and children.

View original record on NIH RePORTER →